Abstract | CONTEXT: METHODS: RESULTS:
Cabergoline normalized hyperprolactinemia and recovered the ovulatory cycle in all patients. All adenomas contracted, and 11 macroadenomas and 29 microadenomas disappeared. Eighty patients (94%) conceived 95 pregnancies, two of which were cabergoline-free second pregnancies. The dose of cabergoline at the first pregnancy was 0.25-9 mg/wk overall and 2-9 mg/wk in the resistant patients. Of the 93 pregnancies achieved on cabergoline, 86 resulted in 83 single live births, one stillbirth, and two abortions; the remaining seven were ongoing. All babies were born healthy, without any malformations. No mothers experienced impaired vision or headache suggestive of abnormal tumor reexpansion throughout pregnancy. CONCLUSION:
|
Authors | Masami Ono, Nobuhiro Miki, Kosaku Amano, Takakazu Kawamata, Toshiro Seki, Rena Makino, Kazue Takano, Shun-ichiro Izumi, Yoshikazu Okada, Tomokatsu Hori |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 95
Issue 6
Pg. 2672-9
(Jun 2010)
ISSN: 1945-7197 [Electronic] United States |
PMID | 20357175
(Publication Type: Journal Article)
|
Chemical References |
- Dopamine Agonists
- Ergolines
- Bromocriptine
- Progesterone
- Prolactin
- Cabergoline
|
Topics |
- Adult
- Birth Weight
- Bromocriptine
(adverse effects, therapeutic use)
- Cabergoline
- Cohort Studies
- Dopamine Agonists
(adverse effects, therapeutic use)
- Drug Resistance
- Ergolines
(adverse effects, therapeutic use)
- Female
- Humans
- Hyperprolactinemia
(complications, drug therapy)
- Infertility, Female
(drug therapy, etiology)
- Magnetic Resonance Imaging
- Pituitary Neoplasms
(complications, pathology)
- Pregnancy
- Pregnancy Complications
(epidemiology)
- Pregnancy Outcome
- Progesterone
(blood)
- Prolactin
(blood)
- Prolactinoma
(complications, pathology)
|